Addendum
Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48
Report documents
-
Addendum
Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48
Additional information
Federal Joint Committee (G-BA)
2017-01-05 A G-BA decision was published.
Project details
- Project no.
- A16-73
- Commission
- Commission awarded on 23.11.2016 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V
Status: Commission completed